Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Apr 14, 2021 9:35am
93 Views
Post# 32991779

RE:RE:I again call for leah to be fired immediately

RE:RE:I again call for leah to be fired immediatelyI believe the responsibility now lies on the shareholder shoulders to vote for an appropriate BOD adjustment, this is definitely the definition of insanity if we as a large shareholder block do not act for change ASAP!

“you can’t drink all day if you don’t start early”



Wino115 wrote: They need to strip Boucher of his "Communications" role too and get a proper PR person or firm in there that knows what they're doing to amplify their interaction with markets, both medical and investor.  He's pretty useless from what I can tell on the PR side.  But it is crazy how Leah would not have done a call around and planted a few questions with their sell siders. She learned a lesson this morning on what a pro would have done. 

Sqidmandon wrote: This is unconscionable - Not a single question, after the launch of Phase 1 cancer and dosing of first patient!  Honestly, there is no way this company could be worse at IR and PR.  This cannot go on like this!  First, the terrible deal, with the beneficiaries selling after minimal gains, while they hold the options.  Then, we have no questions.  I have NEVER been on a public company conference call with ZERO questions.  Please, all of the apologists for this company, DO NOT come in here and try and spinb this - there is no spin to be had.  Ridiculous...




<< Previous
Bullboard Posts
Next >>